Recent Headlines
Within Biotechnology
New Hope in Cancer Treatment for Dogs: PharmaCom BioVet’s Veterinary Oncology Treatment Centers
“We lost three of our Siberian Huskies …close family members, to cancer.” The Bertholds vowed, “We would spend the rest of our lives for the sake of our living dogs — in addition to all other dogs — attempting to find better, improved cancer treatments.” PharmaCom BioVet is truly “a union of compassion and technology.” - March 03, 2009 - PharmaCom BioVet
FDA Regulatory Agenda for 2009 Matches Forecast by Cerulean Associates LLC
The FDA's CDER released its 2009 agenda last week, most of which mirrored many of the 40+ recommendations published by Cerulean Associates in its December 2008 SmarterCompliance newsletter. - March 02, 2009 - Cerulean Associates LLC
AnaSpec Introduces Newest GO™ Peptides - Exendins
Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else. - March 01, 2009 - AnaSpec, EGT Group
Techno-Derm Debuts Clayton Shagal’s Collagen - The First 99% Pure, Professional-Grade Collagen Formulation with 100% Efficacy
Techno-Derm announced today that it’s distributing Clayton Shagal’s Collagen, the first 99% pure, professional-grade collagen formulation on the market able to penetrate protective skin barriers and restore collagen fibrils with 100% efficacy. Comprising about 90% of connective tissue,... - February 27, 2009 - Techno-Derm, LLC
Announcing the Launch of the New 25-OH Vitamin D ELISA: Exceptional Correlation to LC-MS/MS in a User-Friendly, Automatable ELISA Format
Serum measurements of 25-OH vitamin D by ELISA are easy and cost-effective for research laboratories who do not have access to the gold standard method, LC-MS/MS with the new 25-OH vitamin D ELISA kit offered by ALPCO. - February 27, 2009 - ALPCO
AnaSpec Introduces Cost-Effective Replacement for Tetramethyl Rhodamine Maleimides
AnaSpec has introduced a collection of Tetramethylrhodamine C2 maleimides that represent an equally effective and more cost-effective replacement for Tetramethyl rhodamine maleimides. - February 27, 2009 - AnaSpec, EGT Group
Trevigen Releases CultreCoat® Cell Adhesion Assays
Trevigen announces the immediate availability of seven new coated well assay kits for cell adhesion studies. - February 25, 2009 - Trevigen, Inc.
Two FDA Quality Systems Compliance Resources Published
Two new FDA quality systems compliance resources – "Bulletproof Yourself against FDA Enforcement" and "FDA Quality Systems Records Requirements for GLPs, GCPs, GMPs" – have been published by the SmarterCompliance™ newsletter and Cerulean Associates LLC. - February 22, 2009 - Cerulean Associates LLC
AnaSpec Introduces Industry’s First NMHC II Antibodies
AnaSpec has announced the release of the industry’s first provider of nonmuscle myosin class II heavy chain (NMHC) antibodies. Nonmuscle myosin class II proteins belong to the superfamily of actin-based motor proteins. They form hexamer structures composed of two ~200kDa heavy chains (NMHC... - February 22, 2009 - AnaSpec, EGT Group
Medi Introduces Mediven® Sheer & Soft: Stylish and Comfortable Compression Therapy Treatments Now Available
Medi USA, a worldwide leader in medical therapy products, introduces Mediven® Sheer & Soft, a complete line of fashionable, discreet and comfortable compression therapy stockings suitable for day and evening wear. Independently proven to be more sheer and comfortable than leading competitors, Sheer & Soft stockings are available in a variety of colors. - February 20, 2009 - Medi USA
AnaSpec Introduces Industry’s Most Sensitive Luminescent Alkaline Phosphatase Assay Kits
AnaSpec announced the release of the industry’s most sensitive assay kits for the detection of alkaline phosphatase activities. The SensoLyteTM Luminescent Alkaline Phosphatase and SensoLyteTM Luminescent Alkaline Phosphatase ELISA assay kits contain a chemiluminescent substrate capable of... - February 19, 2009 - AnaSpec, EGT Group
Grand Opening of Masy Systems’ Biorepository
State of the Art Biorepository Opening in February 2009. - February 18, 2009 - Masy Systems
Colorado BioScience Association and Four Area Economic Development Groups Tout Colorado’s Strengths to the Medical Device Industry at MD&M West in Anaheim
For three days, representatives from the Colorado BioScience Association -- along with four of the state’s economic development entities -- will be showcasing Colorado’s vast medical device sector at the 25th annual Medical Design & Manufacturing (MD&M) West Expo. The... - February 12, 2009 - Colorado BioScience Association
Anavex Appoints Leading Alzheimer's Disease Expert Dr. Mark Smith to Scientific Advisory Board
Anavex Life Sciences Corp. today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. - February 12, 2009 - Anavex Life Sciences Corp.
Pediatric Brain Tumor Foundation Boosts Research Funding by $8 Million
The Pediatric Brain Tumor Foundation (PBTF) increased its medical research funding commitments by $8.35 million in 2008. The grants consist of an additional $6 million to the PBTF Institute at Duke University; $1 million to the PBTF Institute at the University of California San Francisco and $1... - February 08, 2009 - Pediatric Brain Tumor Foundation
Clinical Trials in Russia. Year 2008.
On February 04, 2009 Synergy Research Group (SynRG), a Russia-based CRO, presented the English version of SynRG Orange Paper Year 2008, a regular analytical report on the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering... - February 07, 2009 - Synergy Research Group
Baxa Corporation Ranks Seventh in ColoradoBiz Magazine’s Top 50 Family-Owned Companies
Englewood-based Baxa Corporation ranks in the top ten among family-owned businesses in the 8th annual ColoradoBiz magazine listing. Baxa is owned and managed by the sons of founder Brian Baldwin. This is the company’s fifth year on the annual ColoradoBiz magazine list. - February 07, 2009 - Baxa Corporation
Memorial Sloan-Kettering Cancer Center Implements New Lab Disinfection System
Genetic researchers have a greener way to keep their labs free from organic contamination. A new technology uses Ultraviolet light to replace manual cleaning. The UV sterilization technology is safe, effective and greener for the environment. - February 05, 2009 - VIGILAIR Systems Inc.
Anavex Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer’s Disease Study
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is... - February 04, 2009 - Anavex Life Sciences Corp.
GeneFluidics Inc. Proteus Robotic System Receives ALA New Product Award
GeneFluidics, Inc. is pleased to announce that their Proteus Robotic System has received the New Product Award from the Association for Laboratory Automation (ALA) at LabAutomation2009. The ALA is an international organization devoted to the study, development, and use of laboratory automation. - February 03, 2009 - GeneFluidics Inc.
AnaSpec Awarded Patent for HiLyte FluorTM Dyes
AnaSpec, Inc. today announced that the U.S. Patent and Trademark Office has issued the company patent number 7,465,810 for “Reactive 1,3’-Crosslinked Carbocyanines and Their Bioconjugates.” - February 01, 2009 - AnaSpec, EGT Group
AnaSpec Introduces SensoLyte™ Anti-MOG (1-125) IgG ELISA Kits - Mouse & Rat
AnaSpec announced the release of 2 new SensoLyteTM Anti-MOG ELISA assay kits – the SensoLyteTM Anti-Mouse MOG (1-125) and SensoLyteTM Anti-Rat MOG (1-125) IgG ELISA Assay Kits. - January 31, 2009 - AnaSpec, EGT Group
Pharmaceutical Processing Magazine Cover Features Cerulean’s 2009 FDA Forecast Under the Obama Administration
Under the Democratic Congress and the Obama administration, the US Food and Drug Administration will take an increasingly tougher line with pharmaceutical, biotech and medical device executives; this according to a new analysis published last week in Pharmaceutical Processing magazine. - January 29, 2009 - Cerulean Associates LLC
IonSense Announces the Expansion of DART® Ion Source Product Line to Include TOF Mass Spectrometers
The Popular Direct Analysis Technique is Now Available for Time-of-Flight Instruments, Expanding the Range of Applications. - January 27, 2009 - IonSense, Inc.
New National Study Reports $1.3 Billion Invested in Colorado Bioscience Companies 2002-Q2 2008, Ranking Colorado 11th in U.S. for Bioscience Venture Capital Investments
Gov. Bill Ritter, the Colorado BioScience Association and Colorado Office of Economic Development released the Colorado Bioscience Roadmap 2008 on January 23. Among findings, the new study reports $1.3 billion was invested in Colorado bioscience companies 2002 through Q2 2008, ranking Colorado 11th in the U.S. for bioscience venture capital investments. - January 27, 2009 - Colorado BioScience Association
AnaSpec Introduces New AnaTagTM HiLyte FluorTM 594 & 680 Protein Labeling Kits
AnaSpec has announced the inclusion of two new dyes in its AnaTagTM protein labeling kit collection - HiLyte FluorTM 594 (Ex/Em=593/616 nm) and HiLyte FluorTM 680 (Ex/Em=678/699 nm). Developed by AnaSpec, HiLyte FluorTM dyes are a series of dyes that spans the whole visible spectrum (Figure... - January 25, 2009 - AnaSpec, EGT Group
Nanion Nominated for the German Industry’s Innovation Award
Nanion is again nominated for a prestigious innovation award, due its impressive product portfolio of automated patch clamp systems. More than 350 companies competed in this year’s Innovation Award and Nanion is finalist in the category “Start-Up Companies.” - January 23, 2009 - Nanion Technologies GmbH
FDA Advice for 2009 Published by Lean Compliance Expert and Cerulean Associates
2009 will be a year of transition for the FDA, with new leadership and renewed Congressional scrutiny, resulting in an agency eager to prove its mettle and toughness on the pharmaceutical, biotech and medical device industries it regulates. - January 18, 2009 - Cerulean Associates LLC
AnaSpec Introduces New ClearPointTM beta-Amyloid Peptides
ClearPointTM peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids. - January 11, 2009 - AnaSpec, EGT Group
BioPortfolio’s Website Traffic Increases Over 500%
BioPortfolio, the leading careers, news and information resource for the life sciences and pharmaceutical industries, experienced dramatic growth in website traffic in 2008. According to Compete™ Inc., a website that offers competitive website traffic metrics, BioPorfolio’s traffic... - January 10, 2009 - BioPortfolio
AnaSpec’s Published References Pass 700
The number of published papers that cite AnaSpec’s products has passed 700. - January 09, 2009 - AnaSpec, EGT Group
Researchers Create Smaller, Brighter Probe, Tailored for Clinical Molecular Imaging and Tumor Targeting
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic. According to the investigators at Memorial Sloan-Kettering Cancer... - December 22, 2008 - Hybrid Silica Technologies Inc.
AnaSpec Introduces Line of Fluorescent Probes for Nucleic Acids
AnaSpec carries a variety of premium quality stains, including cell-impermeant and cell-permeant nucleic acid stains. - December 21, 2008 - AnaSpec, EGT Group
University of New Brunswick and AnaSpec Present Poster at ASCB2008
AnaSpec, in collaboration with the U. of New Brunswick and the Natural Sciences and Engineering Research Council of Canada (NSERC), presented a poster entitled, “The Expression and Activity of MMPs during Zebrafish (Danio rerio) Development." - December 20, 2008 - AnaSpec, EGT Group
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology
Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper... - December 19, 2008 - Anavex Life Sciences Corp.
AnaSpec Introduces Two New IRAK1 Antibodies – pThr 209 & 387
AnaSpec has introduced two new phosphospecific IRAK1 polyclonal antibodies – anti-IRAK1 (pThr 209) and anti-IRAK1 (pThr387). - December 18, 2008 - AnaSpec, EGT Group
Anavex Presents Potent Neuroprotective Effects of Anavex 1-41 at Neuroscience 2008
Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society... - December 17, 2008 - Anavex Life Sciences Corp.
Baxa Announces 2009 Course Dates for Its STAR Center® Training Facility
Baxa Corporation announces record number of course dates for its STAR Center in 2009. Together with the United States Pharmacopeia (USP), the company plans 22 class sessions focused on pharmacy best practice in relation to USP 797 regulatory compliance and hazardous drug handling. The STAR Center, a premier facility designed for cleanroom and pharmacy practice demonstration, is located at the company’s headquarters south of Denver, Colorado. - December 17, 2008 - Baxa Corporation
AnaSpec Introduces Industry’s First Fluorimetric Assay Kit for Aggrecanase-1 Activity Detection
AnaSpec has announced the release of the industry’s first fluorimetric assay optimized to detect ADAMTS-4 (aggrecanase-1) activity - the SensoLyteTM 520 Aggrecanase-1 Assay Kit. A FRET based assay, it is homogeneous and has an emission in the green range (Ex/Em= 490 nm/520 nm). The kit... - December 17, 2008 - AnaSpec, EGT Group
GeneThera Will Test Raw and Processed Milk for Johne’s Disease Due to Evidence Linking Johne’s Disease to Irritable Bowel Syndrome (IBS) and Chron’s Disease
GeneThera will test raw and processed milk for Johne’s disease due to evidence linking Johne’s disease to Irritable Bowel Syndrome (IBS) and Chron’s disease starting January, 2009. GeneThera, Inc. (GTHR.PK), GeneThera announces it will soon begin testing of raw and processed milk... - December 10, 2008 - GeneThera Inc.
Functional Genetics, Inc. Announces Agreement with Elanco, a Division of Eli Lilly and Company
Functional Genetics, Inc., a biotechnology research and development company, announced today that it has reached a collaborative research, license and commercialization agreement with Elanco, the animal health division of Eli Lilly and Company. The agreement establishes the framework for... - December 09, 2008 - Functional Genetics, Inc.
Baxa Features Rapid-Fill™ Colored Labels, PACT™ Products, Exacta-Mix™ 2400 Compounders and Abacus™ Software at the ASHP Mid-Year Clinical Meeting
Baxa Corporation announces its focus on new Rapid-Fill ASF colored label and Productivity and Compliance Tools (PACT) products at the 2008 American Society of Health-System Pharmacists Mid-year Clinical Meeting and Exhibition beginning today at the Orange County Convention Center in Orlando, FL. Also featured in Baxa booth #2249 are the Exacta-Mix™ 2400 Automated Compounder and Abacus™ TPN Calculation Software. - December 08, 2008 - Baxa Corporation
AnaSpec Signs Distribution Agreement with Yope Biotechnology
AnaSpec and Yope Biotechnology Co. Ltd. today announced a non-exclusive distributor agreement that will allow Yope Biotechnology Co. Ltd. to distribute AnaSpec’s catalog and custom products throughout China. AnaSpec’s Director of Sales & Marketing, Violeta Rajkovska, noted,... - December 04, 2008 - AnaSpec, EGT Group
AnaSpec Signs Distribution Agreement with Biogenuix Medsystems
AnaSpec and Biogenuix Medsystems Pvt. Ltd. today announced a non-exclusive distributor agreement that will allow Biogenuix Medsystems Pvt. Ltd. to distribute AnaSpec’s catalog and custom products throughout India. AnaSpec’s Director of Sales & Marketing, Violeta Rajkovska, noted,... - November 28, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New Line of LL-37 GO™ Peptides
LL-37 peptides are AnaSpec’s latest addition to their expansive collection of research-ready, on-demand GO™ Peptides. - November 27, 2008 - AnaSpec, EGT Group
Accugenix Announces New CEO & President, Retains Former as R&D VP; Former COO Roger Nalepa Takes the Reins and Former CEO Doug Smith Refocuses on R&D
Accugenix, Inc. publicly announced today the promotion of former COO, Roger Nalepa, to the position of CEO & President, and the reassignment of former CEO Doug Smith to Vice President of Research & Development. Specializing in genetic microbial identification, the Delaware-based DNA... - November 27, 2008 - Accugenix, Inc.
Baxa Corporation Announces Co-Marketing Agreement with Industry Leaders Pharmacy OneSource, Inc, and ClinicalIQ, LLC
Announcing the collaboration of Baxa Corporation, ClinicalIQ LLC, and Pharmacy OneSource, Inc., bring greater understanding of, and compliance to, USP 797 for the healthcare industry. The alliance among these industry-leading companies provides health-system pharmacies with the tools to stay compliant with the standards set forth by USP. - November 24, 2008 - Baxa Corporation
Biotech Executive John Collar Named Executive Director of the Colorado BioScience Association, Effective December 8
Following an extensive national search, John Collar, Chief Operating Officer of Westminster-based Matrilinex, has been named Executive Director of the Colorado BioScience Association (CBSA), effective December 8, 2008. A seasoned senior executive, Collar has a background of solid corporate experience with a proven track record for strategic planning, managing to metrics, and c-level operational responsibilities. He succeeds Denise Brown, Founding Executive Director of CBSA, who retired Sept 30. - November 24, 2008 - Colorado BioScience Association
AnaSpec Releases 4 New Phosphospecific Anti-Tau Antibodies
AnaSpec is excited to announce the release of 4 more new phosphospecific anti-Tau antibodies. This represents the industry’s largest collection of anti-Tau antibodies - 17 phosphospecific and 9 non-phosphospecific antibodies. AnaSpec’s expertise in phosphopeptide synthesis combined... - November 23, 2008 - AnaSpec, EGT Group
AnaSpec Signs Distribution Agreement with Shanghai Universal Biotech Company
AnaSpec and Shanghai Universal Biotech Company today announced a non-exclusive distributor agreement that will allow Shanghai Universal Biotech Company to distribute AnaSpec’s catalog and custom products throughout China. - November 22, 2008 - AnaSpec, EGT Group